---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-095439"
form_type: "8-K"
ticker: "AWHL"
cik: "0000926617"
company_name: "Aspira Women's Health Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:17:39.529260+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aspira Women's Health Q2 revenue $2.4M; cuts FY cash guidance to $13-14.5M

## Summary
- Q2 product revenue $2.4M vs $2.5M YoY; OvaSuite volume 6,471 units (+3%).
- Gross margin 59% vs 62% YoY; operating cash used $3.7M in Q2.
- Cash at June 30: $1.0M; subsequent raises of $4.0M boosted pro forma cash to $5.0M.
- Full-year 2024 cash guidance lowered to $13-14.5M from $15-18M.
- OvaWatch volume grew 48% YoY; John Kallassy appointed interim CFO effective Aug 15.

## SEC filing metadata
- accession: 0000950170-24-095439
- form_type: 8-K
- ticker: AWHL
- cik: 0000926617
- company_name: Aspira Women's Health Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926617/000095017024095439/0000950170-24-095439-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926617/000095017024095439/awh-20240812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-095439
- JSON: https://secwatch.observer/filing/0000950170-24-095439.json
- Plain text: https://secwatch.observer/filing/0000950170-24-095439.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.